Cargando…

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). Fixed-dose combinations of alogliptin with both metformin and pioglitazone are also commercially available, providing a measure of convenien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holland, Daniel Q, Neumiller, Joshua J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090041/ https://www.ncbi.nlm.nih.gov/pubmed/25050071 http://dx.doi.org/10.2147/DMSO.S37648

Ejemplares similares

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2010)

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
por: Kaku, Kohei, et al.
Publicado: (2019)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index
por: Aoki, Chie, et al.
Publicado: (2017)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin
por: Yin, Hao, et al.
Publicado: (2013)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
por: Derosa, Giuseppe, et al.
Publicado: (2007)

Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
por: Kim, Jeong Mi, et al.
Publicado: (2020)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Pioglitazone alters fat distribution in patients with type 2 diabetes mellitus, in contrast to metformin
por: Jonker, Jacqueline T, et al.
Publicado: (2009)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
por: Ohira, Masahiro, et al.
Publicado: (2014)

Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin
por: Jameshorani, Maryam, et al.
Publicado: (2017)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy: Erratum
Publicado: (2016)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
por: Wang, Hongyu, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

Efficacy and safety of fixed‐dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial
por: Ji, Linong, et al.
Publicado: (2017)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes
por: Esteghamati, Alireza, et al.
Publicado: (2013)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone
por: Tseng, Chin-Hsiao
Publicado: (2019)

Optimizing Multidisciplinary Care of Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
por: Kelepouris, Ellie, et al.
Publicado: (2023)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Derosa, Giuseppe, et al.
Publicado: (2009)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Kay, Stephen, et al.
Publicado: (2017)

Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial
por: Chawla, Shalini, et al.
Publicado: (2013)

Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes
por: Yamazaki, Shunsuke, et al.
Publicado: (2022)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
por: Yamanouchi, Toshikazu
Publicado: (2010)

Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
por: Desouza, Cyrus V., et al.
Publicado: (2010)

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
por: Li, Yan-Rong, et al.
Publicado: (2021)

Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin
por: Breunig, Ian M., et al.
Publicado: (2014)

Randomized, double‐blind, phase III study to evaluate the efficacy and safety of once‐daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes
por: Kaku, Kohei, et al.
Publicado: (2017)

Combination of Metformin and Exercise in Management of Metabolic Abnormalities Observed in Type 2 Diabetes Mellitus
por: Jevtovic, Filip
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jgls9glre7cma61g2b1d8tjobn